Excited to share our review “Challenging the Status Quo for Therapeutic Clinical Trials in Fibrotic Interstitial Lung Diseases” where we discuss the current clinical trial landscape and explore emerging strategies to accelerate the development of therapies for fILD. lnkd.in/guuRdp-w #ILD #curePF

🌟 Save the Date! 🌟 Calgary International Microbiome Summit Oct 5-7, 2027 in Calgary, Canada 🦠🧫🧪🧬🔬🤩 Hosted by @snyderinstitute.bsky.social & @ucalgarymed.bsky.social It’s basically the Microbiome Olympics

The “why” behind every decision is the person in front of us. In this conversation, I joined the Leap Together podcast to discuss the real-world complexity for patients living with pulmonary fibrosis. Listen here: lpcur.com/LeapTogether...  #LeapTogetherPodcast #ClinicalTrials #curePF

The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study Just out in ERJ and led by Dr. Na'ama Avitzur A 🧵👇 (key take-away 👉 sex matters to patients with PF and their disease impacts this) #OpenAccess #CurePF #CureIPF publications.ersnet.org/content/erj/...

The approval of Nerandomilast marks a pivotal step forward in IPF care. For patients living with IPF, this offers long awaited hope and this milestone underscores the collective efforts of multiple stakeholders who never stopped pushing for better therapeutic options for IPF.

Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade. Congratulations to all our patients & yes, better drugs are on the way!! Great day for the #CureIPF community!! #ScienceMatters www.fda.gov/drugs/news-e...

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁 Positive trial 🗞️ Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD @ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social www.theglobeandmail.com/investing/ma...

Heading to #ATS2025 🫁? Wondering about the Clinical Problems assembly content? 📻 Check out this podcast where we break it down for you 👇😁 @ats-clinicalprobs.bsky.social @atsearlycareer.bsky.social

Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....

Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social www.nature.com/articles/s41...

Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?

The ATS CP apprenticeship program is a great way to get involved with the assembly! Get more info and apply here: tinyurl.com/439v6xam Make sure to select the clinical problems assembly and apply before January 24!⏰ #pulmsky #medsky

🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟 Just out in @atsblueeditor.bsky.social 🫁 www.atsjournals.org/doi/abs/10.1... State of the Art: -Epidemiology -Mechanisms of Injury -Implications - clinical & policy -Future directions

Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we? @ipfdoc.bsky.social @kaminskimed.bsky.social #CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social pmc.ncbi.nlm.nih.gov/articles/pmi...

An excellent 🧵on potential application of Mendelian randomization towards target identification and therapeutic development #cureIPF #REMAP-ILD

There’s still time to submit session ideas for #CHEST2025! Don't miss your chance to speak! Need help? Just ask me! info.chestnet.org/chest-call-f...

Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF

Continued awareness and identification of IPF needs to continue.

So excited to hear what @kerrijohannson.bsky.social has to tell us about the impact of our environment on the development of pulmonary fibrosis! The whole lecture will be available on-line via the MTW website: www.imperial.ac.uk/mtw-centre-f...

Really cool! our “Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis” made it to cover of the American Journal of Respiratory & Critical Care Medicine. Kudos to soon to be #DoubleDoc Amy Zhao & crew!! #BestStudents www.atsjournals.org/doi/full/10....

Made my first pilgrimage to ACCP in Glenview, IL this week. Thanks #Chest for the hospitality! @tkulkarni.bsky.social